Henrik Hager

PD-L1 in lung carcinomas

Anti-programmed death receptor-1 (PD-1) and anti-programmed death receptor ligand-1 (PD-L1) therapies have shown promising clinical results in the treatment of non-small cell lung cancer (NSCLC). Anti PD-L1 immunohistochemistry has been shown to be a predictive marker to select patients more likely to respond to these treatments. Several drugs are competing in the same area. These drugs use different companion test as predictive marker. Thus, different anti PD-L1 clones using different visualization systems and different cut of values presents a challenge for the pathologist and the laboratories. The incorporation of this PD-L1 testing in the lung pathology, in the light of sparse material and other mandatory diagnostic and predictive markers, will be discussed.

CV

Henrik Hager has been specialist in pathology since 2006 and is currently consultant and associate clinical professor at Vejle Hospital. Henrik Hager has a background of medical biochemistry and cell biology and have been PhD student, post doc and associate professor at Aarhus University. Henrik Hager’s clinical and research fields are lung cancer, especially prognostic and predictive genetic and epigenetic markers. He has long experience and is co-author of approx. 80 peer reviewed articles and conference posters.

Selected references

  1. Daugaard I, Dominguez D, Kjeldsen TE, Kristensen LS, Hager H, Wojdacz TK, Hansen LL. Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma. Sci Rep. 2016 Oct 26;6:35807.

  2. Filskov Sorensen S, Zhou W, Dolled-Filhart M, Baehr Georgsen J, Wang Z, Emancipator K, Wu D, Busch-Sorensen M, Meldgaard P, Hager H. PD-L1 Expression and Survival Among Advanced Non-Small Cell Lung Cancer Patients Treated With Chemotherapy.Transl Oncol. 2016 Feb;9(1):64-9.

  3. Daugaard I, Kjeldsen TE, Hager H, Hansen LL, Wojdacz TK. The influence of DNA degradation in formalin-fixed, paraffin-embedded (FFPE) tissue on locus-specific methylation assessment by MS-HRM. Exp Mol Pathol. 2015 Dec;99(3):632-40.

  4. Thomsen J, Hjortebjerg R, Espelund U, Ørtoft G, Vestergaard P, Magnusson NE, Conover CA, Tramm T, Hager H, Høgdall C, Høgdall E, Oxvig C, Frystyk J. PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget. 2015 Oct 13;6(31):32266-78.

  5. Jakobsen AK, Lauridsen KL, Samuel EB, Proszek J, Knudsen BR, Hager H, Stougaard M. Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue. Exp Mol Pathol. 2015 Aug;99(1):56-64. doi: 10.1016.

  6. Harders SW, Madsen HH, Hjorthaug K, Arveschoug AK, Rasmussen TR, Meldgaard P, Hoejbjerg JA, Pilegaard HK, Hager H, Rehling M, Rasmussen F. Mediastinal staging in non-small-cell lung carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography. Cancer Imaging. 2014 Jun 3;14(1):23. doi: 10.1186/1470-7330-14-23.

  7. Søes S1, Daugaard IL, Sørensen BS, Carus A, Mattheisen M, Alsner J, Overgaard J, Hager H, Hansen LL, Kristensen LS. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience. 2014 May 23;1(5):367-74. Collection 2014.

  8. Andersen RK, Hammer K, Hager H, Christensen JN, Ludvigsen M, Honoré B, Thomsen MB, Madsen M. Melanoma tumors frequently acquire LRP2/megalin expression, which modulates melanoma cell proliferation and survival rates. Pigment Cell Melanoma Res. 2015 May;28(3):267-80.

  9. von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Büttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Höfler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schäper F, Lenze D, Hummel M, Dietel M. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol. 2014 Nov;9(11):1685-92. doi: 10.1097.